Literature DB >> 28099250

Interleukin-36α Induces Inflammatory Mediators From Human Pancreatic Myofibroblasts Via a MyD88 Dependent Pathway.

Atsushi Nishida1, Osamu Inatomi, Takehide Fujimoto, Hirotsugu Imaeda, Masaji Tani, Akira Andoh.   

Abstract

OBJECTIVES: Interleukin-36 (IL-36) is a recently described proinflammatory cytokine, characterized by the induction of inflammatory mediators. In the present study, we investigated the biological activity and the signal transduction of IL-36α in human pancreatic myofibroblasts.
METHODS: The mRNA and protein expression of inflammatory mediators was evaluated using real-time polymerase chain reaction and enzyme-linked immunosorbent assay, respectively. The expression of IL-36α and its receptor in the pancreatic tissue was evaluated using immunohistochemical technique. Intracellular signaling pathways were evaluated using immunoblotting and specific small interference RNA-transfected cells.
RESULTS: Interleukin-36α and its receptor complex IL-36R/IL-1RAcP were detected in fibrotic tissue of chronic pancreatitis. Interleukin-36α dose- and time-dependently induced the mRNA expression and protein secretion of CXCL1, CXCL8, MMP-1, and MMP-3 from human pancreatic myofibroblasts. Interleukin-36α assembled MyD88 adaptor proteins (MyD88, TRAF6, IRAK1, and TAK1) into a complex. Furthermore, IL-36α induced the phosphorylation of mitogen-activated protein kinases and the activation of nuclear factor κB and activator protein 1. Mitogen-activated protein kinase inhibitors and small interference RNAs specific for nuclear factor κB and activator protein 1 significantly suppressed the protein secretion of inflammatory mediators induced by IL-36α stimulation.
CONCLUSIONS: It was suggested that IL-36α plays an important role in the pathophysiology of inflammation and fibrosis in the pancreas via an autocrine function.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28099250     DOI: 10.1097/MPA.0000000000000765

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  9 in total

1.  Overlapping Roles for Interleukin-36 Cytokines in Protective Host Defense against Murine Legionella pneumophila Pneumonia.

Authors:  Yuta Nanjo; Michael W Newstead; Tetsuji Aoyagi; Xianying Zeng; Kazuhisa Takahashi; Fu Shin Yu; Kazuhiro Tateda; Theodore J Standiford
Journal:  Infect Immun       Date:  2018-12-19       Impact factor: 3.441

2.  TRAF molecules in inflammation and inflammatory diseases.

Authors:  Almin I Lalani; Sining Zhu; Samantha Gokhale; Juan Jin; Ping Xie
Journal:  Curr Pharmacol Rep       Date:  2017-12-20

Review 3.  IL-36 in chronic inflammation and fibrosis - bridging the gap?

Authors:  Michael Elias; Shuai Zhao; Hongnga T Le; Jie Wang; Markus F Neurath; Clemens Neufert; Claudio Fiocchi; Florian Rieder
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

Review 4.  Novel mechanisms and clinical trial endpoints in intestinal fibrosis.

Authors:  Jie Wang; Sinan Lin; Jonathan Mark Brown; David van Wagoner; Claudio Fiocchi; Florian Rieder
Journal:  Immunol Rev       Date:  2021-05-16       Impact factor: 10.983

5.  LncRNA MALAT1 promotes high glucose-induced inflammatory response of microglial cells via provoking MyD88/IRAK1/TRAF6 signaling.

Authors:  Li-Qing Wang; Heng-Jun Zhou
Journal:  Sci Rep       Date:  2018-05-29       Impact factor: 4.379

Review 6.  The Roles of IL-1 Family Cytokines in the Pathogenesis of Systemic Sclerosis.

Authors:  Dan Xu; Rong Mu; Xiaofan Wei
Journal:  Front Immunol       Date:  2019-09-13       Impact factor: 7.561

7.  Long Noncoding RNA GM16343 Promotes IL-36β to Regulate Tumor Microenvironment by CD8+T cells.

Authors:  Deli Mao; Chenrui Hu; Jianglei Zhang; Chao Feng; Zhe Zhang; Jin Wang; Zhongsong Man; Zhongwei Zhu; Yunliang Wang; Hua Zhao; Xinguo Zhu; Jun Ouyang; Xiaoqiang Dong; Xin Zhao
Journal:  Technol Cancer Res Treat       Date:  2019 Jan-Dec

Review 8.  Interleukin-36 Cytokine/Receptor Signaling: A New Target for Tissue Fibrosis.

Authors:  Elaina Melton; Hongyu Qiu
Journal:  Int J Mol Sci       Date:  2020-09-04       Impact factor: 5.923

9.  A potential therapeutic effect of catalpol in Duchenne muscular dystrophy revealed by binding with TAK1.

Authors:  Dengqiu Xu; Lei Zhao; Jingwei Jiang; Sijia Li; Zeren Sun; Xiaofei Huang; Chunjie Li; Tao Wang; Lixin Sun; Xihua Li; Zhenzhou Jiang; Luyong Zhang
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-08-31       Impact factor: 12.910

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.